9 active not recruiting, 6 completed, 5 terminated, 4 recruiting. 15 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Active not recruiting 5, Completed 4, Terminated 3, Recruiting 2, Withdrawn 1 |
| Phase 2 | 14 | Active not recruiting 5, Terminated 4, Completed 2, Recruiting 2, Withdrawn 1 |
Follow Platinum-Resistant Ovarian Carcinoma: new trials by email Literature Review of Platinum-Resistant Ovarian Carcinoma trials Research Report on Platinum-Resistant Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Biopsy, Biospecimen Collection, Niraparib - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-18 | 2025-05-23 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer Atovaquone, Biopsy, Computed Tomography - Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Recruiting | Emory University | 28 | 2023-11-09 | 2026-10-01 |
| Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2023-05-01 | 2026-08-17 |
| PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Biopsy, Pegylated SN-38 Conjugate PLX038, Computed Tomography - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-09-14 | 2026-07-16 |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lenvatinib, Paclitaxel, Pembrolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Floor Backes, MD | 38 | 2021-09-01 | 2026-10-21 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | Ira Winer | 62 | 2020-01-21 | 2026-06-17 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PRGN-3005 UltraCAR-T cells - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Active not recruiting | Precigen, Inc | 71 | 2019-04-30 | 2024-11-08 |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Copanlisib, Niraparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 31 | 2019-04-29 | 2026-07-23 |
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 4 | 2019-03-08 | 2024-09-19 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine - Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2018-10-16 | 2025-04-17 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Anetumab Ravtansine, Bevacizumab, Paclitaxel - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2018-10-12 | 2026-10-13 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Olaparib, Onalespib - Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 28 | 2017-05-19 | 2023-04-26 |
Showing 20 of 25. Sign in to see all of them.
Ovarian Neoplasms (20) · Fallopian Tube Neoplasms (17) · Endometrial Neoplasms (3) · Colorectal Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Triple Negative Breast Neoplasms (2) · Bone Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Disease Progression (1) · Giant Cell Tumor of Bone (1) · Histiocytoma, Malignant Fibrous (1) · Osteosarcoma (1)
Neoplasms (21) · Neoplasms by Site (21) · Adnexal Diseases (20) · Endocrine Gland Neoplasms (20) · Endocrine System Diseases (20) · Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Genital Diseases (20) · Genital Diseases, Female (20) · Genital Neoplasms, Female (20) · Gonadal Disorders (20) · Ovarian Diseases (20) · Urogenital Diseases (20) · Urogenital Neoplasms (20) · Fallopian Tube Diseases (17)
Disulfides (6) · Immunoglobulin G (6) · Taxes (6) · Biopsy (5) · Cyclophosphamide (5) · Paclitaxel (5) · Specimen Handling (5) · Bevacizumab (4) · Gemcitabine (3) · fludarabine (3) · CTLA-4 Antigen (2) · Doxorubicin (2) · Ipilimumab (2) · Leukapheresis (2) · Nivolumab (2)
M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (5) · Mayo Clinic (4) · City of Hope Medical Center (3) · Roswell Park Cancer Institute (2) · Emory University (1) · Floor Backes, MD (1) · Ira Winer (1) · Northwestern University (1) · Precigen, Inc (1)
United States (24) · Canada (2)
Amir A Jazaeri (5) · Amy R. Lankford, PhD (1) · Andrea E. Wahner Hendrickson, M.D. (1) · Brenda J. Ernst, M.D. (1) · Daniela E Matei, M.D. (1) · Emese Zsiros, MD (1) · Evanthia Galanis, M.D. (1) · Floor Backes, MD (1) · Frank S Hodi (1) · Ira Winer, M.D. (1) · James M Cleary (1) · Kunle Odunsi (1) · Lorna Rodriguez (1) · Lorna Rodriguez-Rodriguez (1) · Matthew S. Block, M.D., Ph.D. (1)
PMID 31401903, PMID 32379297, PMID 35264434, PMID 35357903, PMID 38009662, PMID 38236249, PMID 38309721, PMID 38471508, PMID 41528970
UM1CA186709 (3), P30CA016056 (2), P30CA033572 (2), UM1CA186644 (2), P30CA060553 (1), P30CA138292 (1), P50CA136393 (1), R01CA164333 (1), R01CA266874 (1), U01CA062490 (1)